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Abstract: Pseudomonas aeruginosa is a human pathogen associated with a variety of  
life-threatening nosocomial infections. This organism produces a range of virulence factors 
which actively cause damage to host tissues. One such virulence factor is pyocyanin, 
known to play a crucial role in the pathogenesis of P. aeruginosa infections. Previous 
studies had identified a novel compound capable of strongly inhibiting the production of 
pyocyanin. It was postulated that this inhibition results from modulation of an intercellular 
communication system termed quorum sensing, via direct binding of the compound with 
the LasR protein receptor. This raised the possibility that the compound could be an 
antagonist of quorum sensing in P. aeruginosa, which could have important implications 
as this intercellular signaling mechanism is known to regulate many additional facets of  
P. aeruginosa pathogenicity. However, there was no direct evidence for the binding of the 
active compound to LasR (or any other targets). Herein we describe the design and 
synthesis of a biotin-tagged version of the active compound. This could potentially be used 
as an affinity-based chemical probe to ascertain, in a direct fashion, the active compound’s 
macromolecular biological targets, and thus better delineate the mechanism by which it 
reduces the level of pyocyanin production. 








Pseudomonas aeruginosa is an opportunist Gram-negative human pathogen responsible for a 
variety of nosocomical infections and life-threatening diseases in immunocompromised and debilitated 
patients [1,2]. P. aeruginosa infections are notoriously difficult to eradicate, which has been attributed 
to the predilection of P. aeruginosa cells to form antibiotic-resistant biofilms, and high levels of 
intrinsic antibiotic resistance [1–3]. Indeed, multi-drug resistance P. aeruginosa nosocomical 
infections are increasingly being detected across the globe [4]. Thus the exploration of new strategies 
for tackling infections caused by this notorious pathogen is urgently warranted [1,2,5]. The ability of 
P. aeruginosa to cause disease is dependent upon the production of agents called ‘virulence factors’ 
that actively cause damage to host tissues [1,6–8]. The targeting of virulence factors (for example, 
inhibition of their production) has been identified as a potential new therapeutic approach to treating  
P. aeruginosa infections; in principle, this would attenuate the pathogenicity of the bacterium, 
increasing the likelihood that the host immune system can clear the infection before too much tissue 
damage is caused [1,7,9–11]. One of the many virulence factors produced by P. aeruginosa is 
pyocyanin (Figure 1) [12]. There is a large body of evidence that this low molecular weight redox-active 
phenazine dye is important to the pathogenesis of P. aeruginosa infections [1,5,12–14]. Unsurprisingly 
therefore, the inhibition of pyocyanin production has been identified as a potential antivirulence 
strategy against this organism [1,5,14,15]. Indeed, there has been much interest in the discovery of 
compounds with the ability to inhibit pyocyanin biosynthesis in recent years [1,16–20]. 
Figure 1. BHL and OdDHL are two natural AHL autoinducers used by P. aeruginosa in 
quorum sensing. Pyocyanin is a virulence factor produced by P. aeruginosa. Compound 1, 
an abiotic OdDHL-mimic, is capable of strongly inhibiting the production of pyocyanin in 
cultures of wild type P. aeruginosa [1]. 
 
Pyocyanin production in P. aeruginosa is regulated by an intercellular signaling process known as 
quorum sensing [21,22]. Many species of bacteria use quorum sensing systems, which allows for 
concerted interactions between the cells comprising a population [9]. This communication process is 
mediated by small diffusible signaling molecules termed autoinducers [9,20,23]. In the majority of 
Gram-negative species, N-acylated-L-homoserines (AHLs) serve as the autoinducers [20,23]. These are 
produced by LuxI-type synthase enzymes and bind to cyctoplasmic LuxR-type receptors to initiate the 
expression of genes associated with bacterial group processes [1,20,23–25]. In general, each bacterial 
species responds specifically to its own unique AHL(s), and uses different LuxI-type synthases and 
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LuxR-type receptors [23,26]. Two AHL-based quorum sensing systems are present in P. aeruginosa. 
One employs N-butanoyl-L-homoserine lactone (BHL, Figure 1) as the signaling molecule (generated 
by RhlI and detected by RhlR) and the other uses N-(3-oxododecanoyl)-L-homoserine lactone 
(OdDHL, Figure 1, generated by LasI with LasR as the cognate receptor). There is a third quorum 
sensing system in P. aeruginosa which employs a chemically distinct autoinducer (termed the 
Pseudomonas quinolone signal, PQS). The PQS system is interlinked with the two AHL-based systems, 
forming an intricate hierarchical quorum sensing network, with the las system generally regarded as 
standing at the apex [1,23,27,28]. The production of pyocyanin is regulated by RhlR and transcription 
of the rhlR gene itself is regulated by LasR [1,21]. Thus, inhibitors of LasR would be expected to attenuate 
the biosynthesis of pyocyanin [1,20,23,29–31]. The structure of OdDHL, the natural LasR agonist, has 
often been used as a template to guide the design and synthesis of abiotic LasR antagonists [1,11,16,20,23]. 
We recently reported the synthesis of OdDHL analogues containing non-native head groups in place of 
the natural homoserine lactone moiety [1]. These compounds were evaluated for their ability to inhibit 
the production of pyocyanin in cultures of wild type P. aeruginosa, with 1 (Figure 1) found to be the 
most potent (note that compound 1 was not screened in any LasR-based reporter systems). 
Given that 1 is closely related in structure to OdDHL (which is known to interact with the LasR 
receptor) and the fact that pyocyanin production is generally considered to be regulated by LasR-based 
quorum sensing, it was postulated that 1 reduces the level of pyocyanin production by disrupting 
OdDHL-dependent activation of LasR [1]. Experimental evidence suggested that 1 is capable of 
binding to LasR and it was inferred that 1 might be an antagonist of the LasR receptor and an inhibitor 
of LasR-based quorum sensing in P. aeruginosa. This could have important implications; quorum 
sensing is known to regulate many additional facets of P. aeruginosa pathogenicity [15,32–34] and 
there is tremendous interest in finding small molecules that can disrupt AHL-mediated signaling in this 
organism [9,20,23]. However, our previous studies did not provide any direct evidence for an 
interaction between compound 1 and the LasR receptor, or indeed any other molecular targets. We 
were therefore interested in examining the molecular basis for the activity of 1 in more detail. Such 
information should assist in the design of next-generation agents with improved potency. Towards this 
end, we envisaged the design and synthesis of an affinity-based (“pull down”) chemical probe 
incorporating 1. This could potentially be employed in affinity-based (“pull down”) proteomic assays 
in order to directly detect the biological target(s) of 1 and thus better delineate the mechanism by 
which it reduces the level of pycocyanin production in P. aeruginosa [35–41]. 
2. Results and Discussion 
2.1. Probe Design 
Typically, affinity-based probes are composed of the biologically active molecule of interest 
tethered via a chemical linker to an insoluble support [38]. Usually, the probe is then incubated with 
the cell lysate of the relevant organism [42]. The small molecule’s macromolecular targets can then be 
extracted by virtue of specific binding; washing steps are used to remove non-binding proteins, and the 
remaining high affinity binders can be eluted from the support, separated using polyacrylaminde gel 
electrophoresis and identified using various mass spectrometry techniques [35–37,42]. Biotin is often used 
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as an equivalent of an insoluble support (“tag”) in affinity probes, since immobilization on streptavidin 
beads (either before or after incubation with the biological system) is possible by virtue of the strong 
non-covalent biotin-streptavidin interaction [35,37,42]. Indeed, biotinylated probes have been widely used 
for the identification of many small molecule biological targets [38]. An advantage of biotinylated 
probes over solid-phase supports in that they are often cell permeable. Thus in addition to carrying out 
experiments using cell lysates, it is also possible for such probes to be incubated with live cells and 
interact with target protein(s) in their native environment inside a living cell or organism [37]. After cell 
lysis the probe can be pulled out of solution with streptavidin resin, which will also pull out any bound 
protein(s) [37]. Based on these considerations, we targeted the synthesis of 2 (Figure 2), a biotinylated 
affinity probe that could potentially be used for detecting the molecular targets of the active compound 1. 
Figure 2. The target biotinylated affinity probe. 
 
It was decided to use a polyethylene glycol (PEG)-based chain as the linker. PEG chains are 
commonly employed in this regard; they are usually long enough to mitigate undesired steric 
interactions steric hindrance between the support and small molecule-biomolecule interactions [38] 
and flexible enough to allow the target molecule to adopt multiple orientations in three-dimensions 
(and so access a favorable macromolecular binding pose). Furthermore, PEG linkers are also hydrophilic, 
increasing the solubility of molecules in aqueous solution [38]. A crucial consideration when preparing 
an affinity-based probe is where on the molecule of interest the linker should be introduced, as it is 
important that its’ biological activity is not affected significantly [38]. Our previous studies [1] 
indicated that further substitution of the aromatic ring portion would not be appropriate, as the nature 
of the aromatic head group was found to have a profound effect upon the ability of OdDHL-mimics of the 
type of 1 to inhibit pyocyanin production (with strongest inhibition associated with the meta-methoxy 
aromatic ring of 1). There exists a subtle interplay between the structural and electronic properties of 
the aromatic ring group governing compound activity, meaning that the impact of further substitution 
could not be reliably predicted. Furthermore, evidence suggests that the natural 3-oxo-dodecanoyl tail 
group of OdDHL is important for the inhibition of pyocyanin production by compounds which mimic 
the structure of AHLs. We therefore decided to retain the dicarbonyl unit and the nine-carbon alkyl 
chain, and attach the linker at the end of the alkyl chain. 
2.2. Probe Synthesis 
The synthesis of compound 2 (Scheme 1) began with the reaction of 2-(2-(2-chloroethoxy)ethoxy)-
ethanol and sodium azide, which furnished azide 3 in quantitative yield. The desired nine-carbon  
alkyl chain was installed by reaction deprotonation of the hydroxyl group and treatment with  
10-bromodecanoic acid. 
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Scheme 1. The synthesis of biotin-tagged affinity probe 2. rt = room temperature. 
 
The resulting acid 4 was converted to the corresponding acid chloride and reacted with Meldrum’s 
acid to generate adduct 5. Subsequent treatment of this crude material with methanol yielded β-ketoester 6. 
Acetal protection to form 7 was followed by reduction of the azide group to yield 8. Subsequent 
HATU-mediated coupling with D-biotin proceeded smoothly to generate the protected ester 9. 
Hydrolysis using lithium hydroxide provided the carboxylate 10. HATU-mediated coupling of 10 with 
m-anisidine furnished the protected precursor 11 in reasonable yield. Finally, acid-catalyzed 
deprotection provided the desired compound 2. 
Typical affinity-based pull down assays involve the use of one-dimensional (1D) gel electrophoresis 
to separate proteins binding to the bioactive molecule under investigation. However, this method can 
suffer from a lack of sensitivity. We have previously proposed a strategy to address this issue based 
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around combining biotin-mediated affinity capture from cell lysates with 2D difference gel 
electrophoresis (DIGE) [42]. This method of electrophoresis should allow a greater sensitivity 
compared to 1D techniques and thus facilitate the identification of weak binding-protein targets [42]. 
Conceivably, such an approach could be used with the affinity probe 2 in order to elucidate molecular 
targets for the anti-pyocyanin compound 1. 
3. Experimental 
3.1. General 
Reactions were performed using oven-dried glassware under an atmosphere of nitrogen with 
anhydrous, freshly distilled solvents unless otherwise stated. Dichloromethane, ethyl acetate, 
methanol, n-hexane, acetonitrile and toluene were distilled from calcium hydride. Diethyl ether was 
distilled over a mixture of lithium aluminium hydride and calcium hydride. Petroleum ether was 
distilled before use and refers to the fraction between 40–60 °C. All other reagents were used as 
obtained from commercial sources. Room temperature (rt) refers to ambient temperature. 
Temperatures of 0 °C were maintained using an ice-water bath. Reaction times are given either in 
hours (h) or minutes (min) or overnight (approximately 12 h) Yields refer to chromatographically and 
spectroscopically pure compounds unless otherwise stated. All flash chromatography was carried out 
using slurry-packed Merck 9325 Keiselgel 60 silica gel. Where possible, reactions were monitored by 
thin layer chromatography (TLC) performed on commercially prepared glass plates pre-coated with 
Merck silica gel 60 F254 or aluminium oxide 60 F254. Visualisation was by the quenching of UV 
fluorescence (νmax = 254 nm) or by staining with potassium permanganate. Infrared spectra were 
recorded neat or as a solution in the designated solvent on a Perkin-Elmer Spectrum One spectrometer 
with internal referencing. Selected absorption maxima (νmax) are reported in wavenumbers (cm−1). 
Proton magnetic resonance spectra were recorded using an internal deuterium lock at ambient probe 
temperatures (unless otherwise stated) on the following instruments: Bruker DPX-400 (400 MHz), 
Bruker Avance 400 QNP (400 MHz) Bruker Avance 500 BB ATM (500 MHz) and Bruker Avance 
500 Cryo Ultrashield (500 MHz). Chemical shifts (δH) are quoted in ppm, to the nearest 0.01 ppm, and 
are referenced to the residual non-deuterated solvent peak. Coupling constants (J) are reported in 
Hertz. Data are reported as follows: chemical shift, integration, multiplicity [br, broad; s, singlet; d, 
doublet; t, triplet; q, quartet; quint, quintet; sext, sextet; sept, septet; m, multiplet; or as a combination 
of these (e.g., dd, dt, etc.)], coupling constant(s) and assignment. Proton assignments were determined 
either on the basis of unambiguous chemical shift or coupling pattern, by patterns observed in 2D 
experiments (1H-1H COSY, HMBC and HMQC) or by analogy to fully interpreted spectra for related 
compounds. Carbon magnetic resonance spectra were recorded by broadband proton spin decoupling 
at ambient probe temperatures (unless otherwise stated) using an internal deuterium lock on the 
following instruments: Bruker DPX-400 (100 MHz), Bruker Avance 400 QNP (100 MHz) and Bruker 
Avance 500 BB ATM (125 MHz) and Bruker Avance 500 Cryo Ultrashield (125 MHz). Chemical 
shifts (δC) are quoted in ppm, to the nearest 0.1 ppm, and are referenced to the residual non-deuterated 
solvent peak. Assignments were supported by DEPT editing and determined either on the basis of 
unambiguous chemical shift or coupling pattern, by patterns observed in 2D experiments (HMBC and 
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HMQC) or by analogy to fully interpreted spectra for related compounds. The ionisation technique 
used was electron ionisation (EI). High resolution mass spectroscopy measurements were recorded  
in-house using a Waters LCT Premier Mass Spectrometer or a Micromass Quadrapole-Time of Flight 
(Q-ToF) spectrometer. Mass values are reported within the error limits of ±5 ppm mass units. The 
ionisation technique used was electrospray ionization (ESI). Optical rotations were measured in MeOH 
on a Perkin Elmer 343 Polarimeter; [α]D values are reported in 10−1 degrees cm2 g−1 at 589 nm. 
3.2. Experimental Procedures 
2-(2-(2-Azidoethoxy)ethoxy)ethanol (3). To a solution of NaN3 (2.06 g, 32.7 mmol, 1.4 eq.) in DMF 
(10 mL) was added 2-(2-(2-chloroethoxy)ethoxy)ethanol (4 g, 23.8 mmol 1 eq.). The reaction mixture was 
stirred at 100 °C for 5 h and evaporated to dryness. The resulting residue was partitioned between CH2Cl2 
(20 mL) and water (20 mL). The aqueous phase was extracted twice more with CH2Cl2 (2 × 50 mL), the 
organic layers combined, dried over MgSO4 and evaporated to dryness to give 3 as a pale yellow oil 
(4.21 g, 24 mmol, 100%) which was used without further purification. Rf 0.16 (70% EtOAc/bp  
40–60 petroleum ether); νmax (neat)/cm−1: 3400 (broad, O-H), 2869 (C-H), 2099 (N3); 1H-NMR  
(400 MHz, CDCl3) δH 3.73 (2H, t, J = 5.5 Hz, CH2OH), 3.69-3.65 (6H, m, 3 × CH2O), 3.61 (2H, t,  
J = 4.6 Hz, CH2O), 3.30 (2H, t, J = 5.0 Hz, CH2N3), 2.36 (1H, t, J = 6.2 Hz, CH2OH); 13C-NMR  
(101 MHz, CDCl3) δC 72.6 (CH2O), 70.7 (CH2O), 70.5 (CH2O), 70.2 (CH2O), 61.9 (CH2OH), 50.8 (CH2N3). 
10-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)decanoic acid (4). A solution of bromodecanoic acid (909 mg, 
5.2 mmol, 1 eq.), NaI (78 mg, 0.52 mmol, 0.1 eq.) and compound 3 (1.3 g, 5.2 mmol, 1 eq.) in dry 
DMF (10 mL) was cooled to 0 °C and NaH (60% dispersion in mineral oil, 520 mg, 13 mmol, 2.5 eq.) 
was added piecewise. After 20 min the reaction mixture was heated to 55 °C and stirred overnight 
forming an orange gel. The solvent was removed under reduced pressure and the residue was 
partitioned between HClaq (100 mL) and Et2O (100 mL). The aqueous phase was extracted with Et2O 
(2 × 100 mL), the combined organic layers dried over MgSO4 and evaporated to dryness. The resulting 
residue was purified by column chromatography (stepwise gradient, 0%–40% Et2O/bp 40–60 
petroleum ether with 1% acetic acid) to yield 4 (0.789 g, 1.78 mmol, 44%) as a colourless oil. Rf: 0.34 
(40% EtOAc/bp 40–60 petroleum ether, 1% acetic acid); νmax (neat)/cm−1: 3400 (O-H), 2927 (C-H), 
2856 (C-H), 2100 (N3), 1708 (C=O); 1H-NMR (500 MHz, CDCl3) δH 3.70–3.64 (8H, m, 4 × OCH2), 
3.59 (2H, app dd, J = 6.0, 3.8 Hz, OCH2), 3.45 (2H, t, J = 6.8 Hz, OCH2), 3.39 (2H, t, J = 5.1 Hz, 
CH2N3), 2.34 (2H, t, J = 7.5 Hz, HOOCCH2), 1.80–1.50 (4H, m, HOOCCH2CH2 and CH2CH2CH2O), 
1.31 (10H, d, J = 18.8 Hz, 5 × CH2); 13C-NMR (126 MHz, CDCl3) δC 178.3 (HOOCCH2) 71.7 
(CH2O), 70.9 (CH2O), 70.9 (CH2O), 70.8 (CH2O), 70.2 (CH2O), 70.2(CH2O), 50.9 (CH2N3), 33.9 
(HOOCCH2), 29.7 (CH2), 29.5 (CH2), 29.4 (CH2), 29.2 (CH2), 29.1 (CH2), 26.2 (CH2), 24.8 
(HOOCCH2CH2); HRMS (ESI+) m/z found [M+H]+ 346.2354, [C16H32N3O5]+ calculated 345.2342. 
Methyl 12-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)-3-oxododecanoate (6) To a solution of compound 4 
(242 mg, 0.70 mmol, 1 eq) in dry CH2Cl2 (1.5 mL) at rt was added oxalyl chloride (100 μL,  
1.19 mmol, 1.7 eq.) and DMF (10 μL). After stirring at rt for 1 h TLC indicated complete turnover 
(small samples of the reaction mixture were quenched with MeOH), the solvent was removed under 
reduced pressure and the acid chloride was used without further purification. A solution of Meldrum’s 
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acid (101 mg, 0.7 mmol, 1 eq.) in dry CH2Cl2 (1.6 mL) was cooled to 0 °C and pyridine (114 μL,  
1.4 mmol, 2 eq.) was added dropwise over 20 min. The acid chloride in CH2Cl2 (1 mL) was then added 
and the mixture was stirred at 0 °C for a further 2 h. The reaction mixture was allowed to warm to rt 
diluted with CH2Cl2 (10 mL) and poured into ice HCl (2N, 15 mL). The organic layer was washed 
with NaClaq (25 mL), dried over MgSO4 and evaporated to dryness. The resultant crude product 
material was dissolved in methanol (2.5 mL) and heated to reflux with stirring for 5 h. The solvent was 
removed under reduced pressure and the resulting residue was purified by column chromatography 
(40% Et2O/bp 40–60 petroleum ether) to yield 6 (176 mg, 0.416 mmol, 63%) as a pale yellow oil.  
Rf 0.22 (40% Et2O/bp 40–60 petroleum ether); νmax (neat)/cm−1: 2925 (C-H), 2857 (C-H), 2101 (N3), 
1747 (C=O), 1717 (C=O); 1H-NMR (400 MHz, CDCl3) δH 3.74 (3H, s, CH3), 3.70–3.62 (8H, m,  
4 × OCH2), 3.60–3.55 (2H, m, OCH2CH2N3), 3.45 (2H, t, J = 6.77 Hz, CH2CH2CH2O), 3.44 (2H, s, 
COCH2CO) 3.39 (2H, t, J = 5.10 Hz, CH2N3), 2.52 (2H, t, J = 7.37 Hz, COCH2CH2), 1.65–1.51 (4H, 
app. m (also H2O), COCH2CH2CH2 and CH2CH2CH2O), 1.39–1.23 (10H, m, 5 × CH2); 13C-NMR  
(101 MHz, CDCl3) δC 203.0 (CH2COCH2), 167.8 (H3CCO), 71.6 (CH2CH2CH2O), 70.9 (CH2O), 70.9 
(CH2O), 70.8 (CH2O), 70.2 (CH2O), 70.2 (CH2O), 52.5 (H3C), 50.8 (COCH2CO), 49.2 (CH2N3), 43.2 
(COCH2CH2), 29.7 (CH2), 29.5 (CH2), 29.5 (CH2), 29.4 (CH2), 29.1 (CH2), 26.2 (CH2), 23.6 
(COCH2CH2CH2); HRMS (ESI+) m/z found [M+H]+ 424.2411 [C19H35N3O623Na1]+ calculated 424.2418. 
Methyl 2-(2-(9-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)nonyl)-1,3-dioxolan-2-yl)acetate (7). To a solution 
of the β keto ester 6 (100 mg, 0.24 mmol, 1 eq.) in toulene (5 mL) at rt was added tosic acid (12.2 mg, 
0.1 eq.), trimethylorthoformate (0.21 mL, 1.2 mmol, 5 eq.) and ethylene glycol (0.119 mL, 2.13 mmol, 
8.9 eq.) sequentially with stirring. The reaction was left to stir overnight at rt. The toluene was 
removed under reduced pressure and the resulting reside was disolved in CH2Cl2 (10 mL), washed 
with saturated aqueous sodium bicarbonate solution (3 × 10 mL), dried over MgSO4 and evaporated to 
dryness. The resulting crude product was purrified by column chromatography (stepwise gradient,  
10%–40% Et2O/bp 40-60 petroleum ether) to yield 7 (69 mg, 0.148 mmol, 62%) as a colourless oil. Rf: 
0.42 (70% Et2O/bp 40-60 petroleum ether); νmax (neat)/cm−1: 2924 (C-H), 2855 (C-H), 2103 (N3), 1738 
(C=O); 1H-NMR (500 MHz, CDCl3) δH 4.01–3.94 (4H, m, OCH2CH2O (actetal)), 3.69 (3H, s, OCH3),  
3.68–3.65 (8H, m, 4 × CH2O), 3.58 (2H, app dd, J = 3.60, 5.90 Hz, OCH2), 3.45 (2H, t, J = 6.82 Hz, 
CH2CH2CH2O), 3.39 (2H, t, J = 5.12 Hz, CH2N3), 2.66 (2H, s, CH3OOCCH2), 1.85–1.74 (2 H, app. M, 
CCH2), 1.55 (2H, dt, J = 22.0, 11.2 Hz, CH2CH2CH2O), 1.45–1.18 (12H, m, 6 × CH2); 13C (126 MHz, 
CDCl3) δC 170.2 (CH3OOC), 109.6 (CH3OOCCH2CO), 71.7 (CH2CH2CH2O), 70.9 (OCH2), 70.9 (OCH2), 
70.8 (OCH2), 70.2 (OCH2), 70.2 (OCH2), 65.3 (OCH2CH2O acetal), 51.9 (CH3O), 50.9 (CH2N3), 42.6 
(CH3OOCCH2), 37.9 (CCH2), 29.8 (CH2), 29.8 (CH2), 29.6 (CH2), 29.6 (CH2), 29.6 (CH2), 26.2 (CH2), 
23.6 (CCH2CH2). HRMS (ESI+) m/z found [M+H]+ 468.2675 [C21H39N3O723Na1]+ calculated 468.2680. 
Methyl 2-(2-(9-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)nonyl)-1,3-dioxolan-2-yl)acetate (8) To a solution 
of compound 7 (62.0 mg, 0.133 mmol, 1 eq.) in degassed EtOAc (2 mL) under an inert N2 atmosphere 
was added Pd (5% on carbon, 7.8 mg, 0.0037 mmol, 0.028 eq.). The reaction vessel was then purged 
with H2 before being stirred under an atmosphere of H2 for overnight at rt. The reaction mixture was 
filtered through celite (washed with EtOAc) and evaporated to dryness to give compound 8 (52.2 mg, 
0.124 mmol, 94%) as a yellow oil which was used without further purification. νmax (neat)/cm−1: 3373 
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(N-H), 2925 (C-H), 2855 (C-H), 1738 (C=O), 1739 (C=O), 1672; 1H-NMR (500 MHz, CDCl3)  
δH 4.02–3.93 (4H, m, OCH2CH2O (acetal)), 3.69 (3H, s, OCH3), 3.68–3.53 (10H, m, 5 × CH2O), 3.45 
(2H, t, J = 6.84 Hz, CH2CH2CH2O), 2.91 (2H, dt, J = 10.57, 5.16 Hz, CH2NH2), 2.66 (2H, s, 
CH3OOCCH2), 2.36 (2H, br s, CH2NH2), 1.81–1.72 (2 H, app. m, CCH2), 1.55 (2H, m, CH2CH2CH2O), 
1.41–1.23 (12H, m, 6 × CH2); 13C (126 MHz, CDCl3) δC 170.2 (CH3OOC), 109.6 (CH3OOCH2C), 
72.4 (OCH2CH2NH2), 71.7 (CH2CH2CH2O), 70.8 (OCH2), 70.7 (OCH2), 70.4 (OCH2), 70.2 (OCH2), 
65.3 (OCH2CH2O acetal), 51.9 (CH3O), 42.6 (CH3OOCCH2), 41.5 (CH2NH2), 37.9 (CCH2), 29.8 
(CH2), 29.7 (CH2), 29.6 (CH2), 29.6 (CH2), 29.6 (CH2), 26.2 (CH2), 23.6 (CCH2CH2); HRMS (ESI+) 
m/z found [M+H]+ 420.2947 [C21H42N3O7]+ calculated 420.2956. 
Methyl 2-(2-(5-oxo-1-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-9,12,15-trioxa-
6-azatetracosan-24-yl)-1,3-dioxolan-2-yl)acetate (9) To a solution of D-biotin (31.2 mg, 0.128 mmol, 
1.16 eq.) in DIPEA (1.77 mL) at rt was added HATU (41.7 mg, 0.110 mmol, 1 eq.) with stirring.  
The solution was stirred for a further 15 min before the addition of compound 8 (46 mg, 0.110 mmol,  
1 eq.). This was stirred at rt overnight. The reaction was quenched by the addition of MeOH (1 mL), 
the solvent removed under reduced pressure and the resulting residue purified by column 
chromatography (stepwise gradient, 1%–10% MeOH/CH2Cl2) to give 9 (50.9 mg, 0.079 mmol, 72%) 
as a sticky pink syrup. Rf: 0.21 (5% MeOH/CH2Cl2); νmax (neat)/cm−1: 3294 (N-H amide), 2926 (C-H), 
2854 (C-H), 1739 (C=O), 1700 (C=O), 1645 (C=O); 1H-NMR (500 MHz, CDCl3) δH 6.56 (1H, br s, 
OCH2CH2NHCO), 5.99 (1H, br s, NHCONH), 5.17 (1H, br s, NHCONH), 4.49–4.43 (1H, m, 
CONHCHCH2S), 4.30–4.23 (1H, m, NHCHCHS), 3.94–3.86 (4H, m, OCH2CH2O acetal), 3.62 (3H, s, 
CH3O), 3.59–3.54 (6H, m, 3 × OCH2), 3.53–3.47 (4H, m, OCH2 and OCH2CH2NH), 3.37 (4H, m, 
CH2CH2CH2O and OCH2CH2NH), 3.09 (1H, dd, J = 11.10, 6.89 Hz, NHCHCHS), 2.85 (1H, dd,  
J = 12.75, 4.47 Hz, CONHCHCHHS), 2.85 (1H, d, J = 12.77 Hz, CONHCHCHHS), 2.59 (2H, s, 
CH3OOCCH2), 2.22–2.11 (2H, m, NHCOCH2CH2CH2), 1.74–1.68 (2H, app. m, CCH2), 1.67–1.54 
(4H, m, NHCOCH2CH2CH2), 1.50 (2H, dt, J = 13.94, 6.83 Hz, CH2CH2CH2CH2O), 1.38 (2H, dt,  
J = 14.93, 7.52 Hz, NHCOCH2CH2CH2), 1.34–1.27 (2H, m, CCH2CH2), 1.27–1.16 (10H, m, 5 × CH2); 
13C-NMR (126 MHz, CDCl3) δC 173.4 (CH2NHCOCH2), 170.2 (CH3OOC), 163.6 (NHCONH), 109.6 
(CH2CCH2), 71.7 (CH2CH2CH2O), 70.7, (OCH2), 70.6 (OCH2), 70.3 (OCH2), 70.2 (OCH2), 70.0 
(OCH2), 65.3 (OCH2CH2O acetal), 62.0 (NHCHCHS), 60.4 (NHCHCH2S), 55.4 (NHCHCHS), 51.9 
(CH3O), 42.6 (COCH2C), 40.7 (NHCHCH2S), 39.4 (OCH2CH2NH), 37.9 (COCH2CCH2), 35.9 
(NHCOCH2CH2CH2), 29.8 (CH2), 29.8 (CH2), 29.7 (CH2), 29.7 (CH2), 29.6 (CH2), 28.2 (CH2), 28.1 
(CH2), 26.2 (CH2), 25.6 (CH2), 23.6 (CCH2CH2); HRMS (ESI+) m/z found [M+H]+ 646.3278 
[C31H56N3O9S]+ calculated 646.3732; [α]26.7 D  +28 (c = 0.917 mmol in MeOH). 
Lithium 2-(2-(5-oxo-1-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-9,12,15-trioxa-
6-azatetracosan-24-yl)-1,3-dioxolan-2-yl)acetate (10) Compound 9 (48 mg, 0.074 mmol, 1 eq.) was 
dissolved in 66% aqueous MeOH (5 mL), lithium hydroxide monohydrate (21 mg, 0.5 mmol, 6.8 eq.) 
was added and the reaction stirred overnight at rt. The solvent was removed under reduced pressure to 
give a mixture of compound 10 and LiOH (69 mg) which was used without further purification.  
νmax (neat)/cm−1: 3277 (N-H amide), 2924 (C-H), 2854 (C-H), 1686 (C=O), 1593 (C=O); 1H-NMR 
(500 MHz, CD3OD) δH 4.46 (1H, ddd, J = 7.85, 4.94, 0.73 Hz, NHCHCH2S), 4.27 (1H, dd, J = 7.88, 
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4.47 Hz, NHCHCHS)), 4.03–3.80 (4H, m, OCH2CH2O acetal), 3.65–3.57 (6H, m, 3 × OCH2), 3.55 
(2H, m, OCH2), 3.51 (2H, t, J = 5.46 Hz, OCH2CH2NH), 3.44 (2H, t, J = 6.65 Hz, CH2CH2CH2O), 
3.33 (2H, t, J = 5.33 Hz, OCH2CH2NH), 3.20–3.14 (1H, m, NHCHCHS), 2.90 (1H, dd, J = 12.75, 5.00 
Hz, CONHCHCHHS), 2.67 (1H, d, J = 12.72 Hz, CONHCHCHHS), 2.43 (2H, s, CH3OOCCH2), 2.19 
(2H, t, J = 7.40 Hz, NHCOCH2CH2CH2), 1.82–1.76 (2H, app. m, CCH2), 1.75–1.49 (6H, m, 3 × CH2),  
1.45–1.34 (m, 4H, 2 × CH2), 1.34–1.19 (10H, m, 5 × CH2); 13C-NMR (126 MHz, CD3OD) δC 178.3 
(CO), 176.2 (CO), 166.1 (NHCONH), 111.6 (CH2CCH2), 72.4 (CH2CH2CH2O), 71.6 (OCH2), 71.6 
(OCH2), 71.3 (OCH2), 71.1 (OCH2), 70.6 (OCH2), 65.8 (OCH2CH2O acetal), 63.4 (NHCHCHS), 61.6 
(NHCHCH2S), 57.0 (NHCHCHS), 47.0 (COCH2CO), 41.1 (NHCHCH2S), 40.4 (OCH2CH2NH), 38.7 
(COCH2CCH2), 36.7 (NHCOCH2CH2CH2), 31.0 (CH2), 30.7 (CH2), 30.7 (CH2), 30.7 (CH2), 30.6 
(CH2), 29.8 (CH2), 29.5 (CH2), 27.2 (CH2), 26.9 (CH2), 24.6 (CCH2CH2); HRMS (ESI+) m/z found 
[M+H]+ 632.3584 [C30H59N3O9S]+ calculated 632.3575. 
N-(2-(2-(2-((9-(2-(2-((3-Methoxyphenyl)amino)-2-oxoethyl)-1,3-dioxolan-2-yl)nonyl)oxy)ethoxy)ethoxy) 
ethyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide (11) To a solution 
of m-anisidine (16 µL, 0.142 mmol, 2 eq.) in a solution of DIPEA (12.2 µL) and DMF (1 mL) at rt was 
added HATU (27 mg, 0.071 mmol, 1 eq.) with stirring. The solution was stirred for a further 15 min 
before the addition of the crude compound 10 (65.3 mg, ≈0.071 mmol, 1 eq.). This was stirred at rt 
overnight. The reaction was quenched by the addition of MeOH (1 mL), the solvent removed under 
reduced pressure and the resulting residue purified by column chromatography (stepwise gradient,  
1%–7% MeOH/CH2Cl2) to give 11 (18.4 mg, 0.025 mmol, 35% over two steps) as a sticky pale orange 
residue. Rf: 0.5 (10% MeOH/CH2Cl2); νmax (neat)/cm−1: 3647 (N-H amide) 3437 (N-H amide) 2926 
(C-H), 2853 (C-H), 1662 (C=O), 1609 (C=O), 1544 (C=O); 1H-NMR (400 MHz, CD3OD) δH 9.53 
(1H, br s, CNHCO), 7.30 (1H, dd, J = 4.27, 2.09 Hz, CH3OCCHCNH), 7.23 (1H, t, J = 8.15 Hz, 
CCHCHCHC), 7.08 (1H, ddd, J = 8.07, 1.76, 0.76 Hz, CCHCHCHC), 6.70 (1H, ddd, J = 8.28, 2.48, 
0.73 Hz, CCHCHCHC), 4.52 (1H, dd, J = 7.90, 4.33 Hz, NHCHCH2S), 4.33 (1H, dd, J = 7.90, 4.40 Hz, 
NHCHCHS), 4.14–3.88 (4H, m, OCH2CH2O acetal), 3.81 (3H, s, CH3O), 3.71–3.59 (8H, m, 4 × OCH2), 
3.57 (2H, t, J = 5.45 Hz, OCH2CH2NH), 3.50 (2H, t, J = 6.63 Hz, CH2CH2CH2O), 3.39 (2H, t, J = 5.41 Hz, 
OCH2CH2NH), 3.22 (1H, dt, J = 27.40, 11.44 Hz, NHCHCHS), 2.96 (1H, dt, J = 12.74, 4.17 Hz, 
CONHCHCHHS), 2.73 (1H, d, J = 13.8 Hz, CONHCHCHHS), 2.71 (2H, s, NHCOCH2CO), 2.25 (2H, 
t, J = 7.38 Hz, NHCOCH2CH2CH2), 1.84–1.54 (8H, m, 4 × CH2), 1.54-1.42 (4H, m, 2 × CH2), 1.43–1.28 
(10H, m, 5 × CH2); 13C-NMR (126 MHz, CD3OD) δC 176.1 (CO), 170.7 (CO), 167.6 (NHCONH), 
166.1 (CH3OC), 140.9 (CHCNH), 130.5 (CH-Ar), 117.0 (COCH2C), 113.4 (CH-Ar), 110.7 (CH-Ar), 
107.1 (CH-Ar), 72.4 (CH2CH2CH2O), 71.6 (OCH2), 71.6 (OCH2), 71.3 (OCH2), 71.1 (OCH2), 70.6 
(OCH2), 64.3 (OCH2CH2O acetal), 63.4 (NHCHCHS), 61.7 (NHCHCH2S), 57.0 (NHCHCHS), 55.7 
(CH3O), 43.9 (NCOCH2CO), 41.0 (CONHCHCH2S), 40.4 (OCH2CH2NH), 39.1 (COCH2CCH2), 36.7 
(NHCOCH2CH2CH2), 30.7 (CH2), 30.5 (CH2), 30.5 (CH2), 30.5 (CH2), 30.4 (CH2), 29.8 (CH2), 29.5 
(CH2), 27.2 (CH2), 26.9 (CH2), 24.5 (CCH2CH2); HRMS (ESI+) m/z found [M+H]+ 737.4138 
[C37H61N4O9S]+ calculated 737.4154; [α]26.7 D  +27 (c = 2.183 mmol in MeOH). 
N-(3-Methoxyphenyl)-3-oxo-12-(2-(2-(2-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-
4-yl)pentanamido)ethoxy)ethoxy)ethoxy)dodecanamide (2) Compound 11 (11.0 mg, 0.015 mmol, 1 eq.) 
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was dissolved in CH2Cl2 (0.5 mL) with TFA (160 µL, 2.09 mmol, 139 eq.) in a flask open to the air 
and stirred for 3 h at rt. The solvent was removed under reduced pressure and the resulting residue 
purified by column chromatography (stepwise gradient, 1%–7% MeOH/CH2Cl2) to yield the  
final compound 2 (10.1 mg, 0.146 mmol, 97%) as a colourless sticky residue. Rf: 0.51 (10% 
MeOH/CH2Cl2); νmax (neat)/cm−1: 3641 (N-H amide) 3294 (N-H amide) 2926 (C-H), 2853 (C-H), 
1682 (C=O), 1629 (C=O), 16411 (C=O), 1544 (C=O); 1H-NMR (500 MHz, CD3OD) δH 7.30 (1H, t,  
J = 2.20 Hz, CH3OCHCNH), 7.22 (1H, t, J = 8.16 Hz, CCHCHCHC), 7.07 (1H, ddd, J = 8.04, 1.91,  
0.85 Hz, CCHCHCHC), 6.70 (1H, ddd, J = 8.27, 2.49, 0.79 Hz, CCHCHCHC), 4.54–4.46 (1H, m, 
CONHCHCH2S), 4.32 (1H, dd, J = 7.86, 4.50 Hz, NHCHCHS), 3.80 (3H, s, CH3O), 3.70–3.58 (8H, 
m, 4 × CH2O), 3.56 (2H, t, J = 5.5 Hz, OCH2CH2NH2), 3.52–3.44 (2H, m,CH2CH2CH2O), 3.42–3.36 
(m, 4H, OCH2CH2NH and COCH2CO), 3.24–3.16 (1H, m, NHCHCHS), 2.94 (1H, dt, J = 12.76, 4.97 
Hz, CONHCHCHHS), 2.72 (1H, d, J = 12.72 Hz, CONHCHCHHS), 2.63 (2H, t, J = 7.28 Hz, 
COCH2COCH2), 2.24 (2H, t, J = 7.35 Hz, NHCOCH2CH2), 1.82–1.52 (8H, m, 4 × CH2), 1.53–1.10 
(14H, m, 7 × CH2); 13C-NMR (126 MHz, CD3OD) δC 206.8 (NHCOCH2CO), 176.1 (CNHCOCH2CO) 
167.6 (OCH2CH2NHCO), 166.1 (NHCONH), 161.6 (CH3OC), 140.7 (CHCNH), 130.6 (CH Ar), 
113.31 (CH Ar), 110.9 (CH Ar), 107.0 (CH Ar), 72.4 (CH2CH2CH2O), 71.6 (OCH2), 71.6 (OCH2), 
71.3 (OCH2), 71.1 (OCH2), 70.6 (OCH2), 63.4 (NHCHCHS), 61.6 (NHCHCH2S), 57.0 (NHCHCHS), 
55.7 (CH3O), 49.9 (COCH2CO) 43.9 (COCH2COCH2), 41.5 (CONHCHCH2S), 40.4 (OCH2CH2NH), 
36.7 (NHCOCH2CH2CH2) 30.7 (CH2), 30.5 (CH2), 30.5 (CH2), 30.4 (CH2), 30.10 (CH2), 29.8 (CH2), 
29.5 (CH2), 27.2 (CH2), 26.9 (CH2), 24.5 (COCH2CH2); HRMS (ESI+) m/z found [M+H]+ 693.11 
[C35H57N4O8S]+ calculated 693.3892; [α]26.8 D  +28 (c = 2.183 mmol in MeOH). 
4. Conclusions 
We have reported the efficient synthesis of 2, a biotin-tagged derivative of a potent inhibitor 1 of the 
production of the virulence factor pyocyanin in the pathogenic bacterium P. aeruginosa. Compound 2 
could potentially be used as a chemical probe in affinity “pull-down” assays in order to identify the 
biological target(s) of 1 and thus help to elucidate the mechanism by which it exerts this biological 
effect. Such information should prove useful in the design of more potent compounds. If 2 is found to 
bind to LasR, this would strongly suggest that 1 is a direct antagonist of quorum sensing in  
P. aeruginosa and, as such, it would represent a valuable molecular tool for the study and 
manipulation of this signaling pathway. The binding studies are currently in progress and the results of 
these investigations will be reported in due course [43]. 
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